Join Growin Stock Community!

Eikon therapeutics, inc. common stockEIKN.US Overview

US StockHealthcare
(No presentation for EIKN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EIKN AI Insights

EIKN Overall Performance

EIKN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EIKN Recent Performance

-3.13%

Eikon therapeutics, inc. common stock

3.59%

Avg of Sector

-1.22%

S&P500

EIKN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EIKN Key Information

EIKN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EIKN Profile

Price of EIKN

EIKN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EIKN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.12
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.12
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EIKN's latest earnings report released?

    The most recent financial report for Eikon therapeutics, inc. common stock (EIKN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EIKN's short-term business performance and financial health. For the latest updates on EIKN's earnings releases, visit this page regularly.

  • How much debt does EIKN have?

    As of the end of the reporting period, Eikon therapeutics, inc. common stock (EIKN) had total debt of 240.73M, with a debt ratio of 0.37. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EIKN have?

    At the end of the period, Eikon therapeutics, inc. common stock (EIKN) held Total Cash and Cash Equivalents of 105.27M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.